Our portfolio company FundaMental Pharma today announces the publication of a groundbreaking study by scientific founders Prof. Hilmar Bading and Dr. Jing Yan, in the renowned scientific journal ‘Cell Reports Medicine’.
The study provides pre-clinical proof of concept data for the therapeutic effect of FundaMental Pharma’s small molecule TwinF interface inhibitor (FP802) in amyotrophic lateral sclerosis (ALS). FundaMental Pharma’s TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. While FundaMental’s current focus is on ALS and Huntington’s Disease, the applicability of these molecules could extend to a range of neurogenerative disorders such as dementia and aging-related memory loss.
The full paper can be read online here: